|
|
|||
|
|||
|
|
|||
|
haldol palliative care |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
haldol palliative care Manufacturer: Ortho-McNeil Prescribing Information
Haloperidol decanoate is almost insoluble in water (0.01 mg/mL), but is solublein most organic solvents haldol palliative care. Each mL of HALDOL Decanoate 50 for IM injection contains 50 mg haloperidol(present as haloperidol decanoate 70.52 mg) in a sesame oil vehicle, with 1.2%(w/v) benzyl alcohol as a preservative haldol palliative care. Each mL of HALDOL Decanoate 100 for IM injection contains 100 mg haloperidol(present as haloperidol decanoate 141.04 mg) in a sesame oil vehicle, with 1.2%(w/v) benzyl alcohol as a preservative haldol palliative care.
Administration of haloperidol decanoate in sesame oil results in slow and sustainedrelease of haloperidol haldol palliative care. The plasma concentrations of haloperidol gradually rise,reaching a peak at about 6 days after the injection, and falling thereafter,with an apparent half-life of about 3 weeks haldol palliative care. Steady state plasma concentrationsare achieved after the third or fourth dose haldol palliative care. The relationship between dose ofhaloperidol decanoate and plasma haloperidol concentration is roughly linearfor doses below 450 mg haldol palliative care. It should be noted, however, that the pharmacokineticsof haloperidol decanoate following intramuscular injections can be quite variablebetween subjects haldol palliative care.
HALDOL is contraindicated in severe toxic central nervous system depressionor comatose states from any cause and in individuals who are hypersensitiveto this drug or have Parkinson's disease haldol palliative care.
Both the risk of developing tardive dyskinesia and the likelihood that it willbecome irreversible are believed to increase as the duration of treatment andthe total cumulative dose of antipsychotic drugs administered to the patientincrease haldol palliative care. However, the syndrome can develop, although much less commonly, afterrelatively brief treatment periods at low doses haldol palliative care. There is no known treatment for established cases of tardive dyskinesia, althoughthe syndrome may remit, partially or completely, if antipsychotic treatmentis withdrawn haldol palliative care. Antipsychotic treatment, itself, however, may suppress (or partiallysuppress) the signs and symptoms of the syndrome and thereby may possibly maskthe underlying process haldol palliative care. The effect that symptomatic suppression has upon thelong-term course of the syndrome is unknown haldol palliative care. Given these considerations, antipsychotic drugs should be prescribed in a mannerthat is most likely to minimize the occurrence of tardive dyskinesia haldol palliative care. Chronicantipsychotic treatment should generally be reserved for patients who sufferfrom a chronic illness that 1) is known to respond to antipsychotic drugs, and2) for whom alternative, equally effective, but potentially less harmful treatmentsare not available or appropriate haldol palliative care. In patients who do require chronic treatment,the smallest dose and the shortest duration of treatment producing a satisfactoryclinical response should be sought haldol palliative care. The need for continued treatment shouldbe reassessed periodically haldol palliative care. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics,drug discontinuation should be considered haldol palliative care. However, some patients may requiretreatment despite the presence of the syndrome haldol palliative care. (For further information aboutthe description of tardive dyskinesia and its clinical detection, please referto ADVERSE REACTIONS .) Neuroleptic Malignant Syndrome (NMS)-- A potentially fatal symptom complexsometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reportedin association with antipsychotic drugs haldol palliative care. Clinical manifestations of NMS arehyperpyrexia, muscle rigidity, altered mental status (including catatonic signs)and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia,diaphoresis, and cardiac dysrhythmias) haldol palliative care. Additional signs may include elevatedcreatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure haldol palliative care. The diagnostic evaluation of patients with this syndrome is complicated haldol palliative care. Inarriving at a diagnosis, it is important to identify cases where the clinicalpresentation includes both serious medical illness (e.g., pneumonia, systemicinfection, etc.) and untreated or inadequately treated extrapyramidal signsand symptoms (EPS) haldol palliative care. Other important considerations in the differential diagnosisinclude central anticholinergic toxicity, heat stroke, drug fever and primarycentral nervous system (CNS) pathology haldol palliative care. The management of NMS should include 1) immediate discontinuation of antipsychoticdrugs and other drugs not essential to concurrent therapy, 2) intensive symptomatictreatment and medical monitoring, and 3) treatment of any concomitant seriousmedical problems for which specific treatments are available haldol palliative care. There is no generalagreement about specific pharmacological treatment regimens for uncomplicatedNMS haldol palliative care. If a patient requires antipsychotic drug treatment after recovery from NMS,the potential reintroduction of drug therapy should be carefully considered haldol palliative care. The patient should be carefully monitored, since recurrences of NMS have beenreported haldol palliative care. Hyperpyrexia and heat stroke, not associated with the above symptom complex,have also been reported with HALDOL haldol palliative care. General-- A number of cases of bronchopneumonia, some fatal, have followedthe use of antipsychotic drugs, including HALDOL (haloperidol) haldol palliative care. It has beenpostulated that lethargy and decreased sensation of thirst due to central inhibitionmay lead to dehydration, hemoconcentration and reduced pulmonary ventilation haldol palliative care. Therefore, if the above signs and symptoms appear, especially in the elderly,the physician should institute remedial therapy promptly haldol palliative care. Although not reported with HALDOL, decreased serum cholesterol and/or cutaneousand ocular changes have been reported in patients receiving chemically-relateddrugs haldol palliative care.
If concomitant antiparkinson medication is required, it may have to be continuedafter HALDOL Decanoate 50 or HALDOL Decanoate 100 is discontinued because ofthe prolonged action of haloperidol decanoate haldol palliative care. If both drugs are discontinuedsimultaneously, extrapyramidal symptoms may occur haldol palliative care. The physician should keepin mind the possible increase in intraocular pressure when anticholinergic drugs,including antiparkinson agents, are administered concomitantly with haloperidoldecanoate haldol palliative care. In patients with thyrotoxicosis who are also receiving antipsychotic medication,including haloperidol decanoate, severe neurotoxicity (rigidity, inability towalk or talk) may occur haldol palliative care. When HALDOL is used to control mania in bipolar disorders, there may be a rapidmood swing to depression haldol palliative care. Information for Patients The use of alcohol with this drug should be avoided due to possible additiveeffects and hypotension haldol palliative care. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| hhaldol palliative care haaldol palliative care halldol palliative care halddol palliative care haldool palliative care haldoll palliative care haldol palliative care haldol ppalliative care haldol paalliative care haldol pallliative care haldol pallliative care haldol palliiative care haldol palliaative care haldol palliattive care haldol palliatiive care haldol palliativve care haldol palliativee care haldol palliative care haldol palliative ccare haldol palliative caare haldol palliative carre haldol palliative caree aldol palliative care hldol palliative care hadol palliative care halol palliative care haldl palliative care haldo palliative care haldolpalliative care haldol alliative care haldol plliative care haldol paliative care haldol paliative care haldol pallative care haldol pallitive care haldol palliaive care haldol palliatve care haldol palliatie care haldol palliativ care haldol palliativecare haldol palliative are haldol palliative cre haldol palliative cae haldol palliative car h aldol palliative care ha ldol palliative care hal dol palliative care hald ol palliative care haldo l palliative care haldol palliative care haldol palliative care haldol p alliative care haldol pa lliative care haldol pal liative care haldol pall iative care haldol palli ative care haldol pallia tive care haldol palliat ive care haldol palliati ve care haldol palliativ e care haldol palliative care haldol palliative care haldol palliative c are haldol palliative ca re haldol palliative car e haldol palliative care ahldol palliative care hladol palliative care hadlol palliative care halodl palliative care haldlo palliative care haldo lpalliative care haldolp alliative care haldol aplliative care haldol plaliative care haldol palliative care haldol palilative care haldol pallaitive care haldol pallitaive care haldol palliaitve care haldol palliatvie care haldol palliatiev care haldol palliativ ecare haldol palliativec are haldol palliative acre haldol palliative crae haldol palliative caer ahaldol palliative care thehaldol palliative care haldol palliative care | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
